Close Menu

USPTO

Continuing litigation that began in 2012, Illumina alleges that Qiagen's GeneReader infringes on a patent it holds related to sequencing-by-synthesis technology.

The First Call

The parties involved in the CRISPR patent fight recently held a conference call, Stat News reports.

A patent examiner has issued an Initial Interference Memo in the CRISPR patent fight, possibly leading to an interference proceeding, according to the Law and Biosciences Blog.

The report, which takes a look at patent issues as it relates to confirmatory genetic tests, acknowledged that federal legislation has dramatically changed the landscape in recent years.

Piece of the Patents

Researchers report in PLOS One on their examination of the percentage of women represented on patent filings.

Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435

Title: Construction of Protein-responsive shRNA/RNAi Control System Using RNP Motif
Patent Number: 8,871,437

NEW YORK (GenomeWeb) – The US Patent and Trademark Office appeals board has invalidated certain claims on a patent held by Illumina that is the subject of an infringement lawsuit by the company against Qiagen's Intelligent Bio-Systems.

Title: RNA Interference-mediating Small RNA Molecules
Patent Number: 8,853,384
Filed: Dec. 2, 2009

Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013

Pages

A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.

Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.

The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.

In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.